Earnings call transcript: CNO Financial Q2 2025 beats forecasts, shares dip

CNO Financial Group reported robust Q2 2025 results, significantly exceeding revenue forecasts with $1.15 billion and slightly beating EPS at $0.87, fueled by record new annualized premiums and strong digital sales growth. Despite this operational outperformance and a 13-year dividend increase streak, the stock saw a modest post-earnings decline, indicating cautious market sentiment. Management reaffirmed its 2025 operating ROE target of 10.5%, highlighting its distinct positioning in the middle-income market and continued capital returns through aggressive share buybacks, while exploring further ROE accretion via its Bermuda operations.

Analysis

CNO Financial Group (CNO) reported a robust second quarter for 2025, characterized by significant operational outperformance that was met with a muted market reaction. The company's revenue of $1.15 billion massively surpassed the $747.79 million forecast by 53.79%, while its earnings per share of $0.87 narrowly beat the $0.86 estimate. This performance was driven by record-breaking growth metrics, including a 17% increase in new annualized premiums to $120 million and a 19% rise in annuity collected premiums to $500 million. A key driver of this momentum is the successful expansion of its direct-to-consumer channel, where digital sales surged by 39% and now constitute 30% of business-to-consumer transactions. Despite these strong fundamentals and an aggressive capital return program that included $117 million in share repurchases, the stock declined 1.04% to $37.58 post-announcement. During the earnings call, management differentiated its stable Medicare Supplement business, which allows for annual repricing and has a 10% rate filing planned for 2025, from the more volatile Medicare Advantage market. The company reaffirmed its guidance for a 10.5% operating ROE in 2025, signaling confidence in its strategy focused on the middle-income market and its ability to generate consistent results.

Key Decisions for Investors

• Given the significant revenue beat and strong operational momentum contrasted with the negative stock reaction, investors may consider the current price level an opportunity, especially as management reaffirmed its ROE targets and analyst price targets suggest upside.
• Investors should closely monitor the impact of the planned 10% rate filing for Medicare Supplement plans in 2025, as its successful implementation is critical to protecting insurance margins against the noted increase in claims utilization.
• The lack of guidance on potential transactions with its Bermuda reinsurance entity presents a potential unpriced catalyst; any future announcements regarding its use could provide meaningful ROE accretion beyond current expectations.
• Consider the company's defensive positioning within the insurance sector, as its focus on manufacturing Medicare Supplement products and serving a niche middle-income annuity market insulates it from the competitive and regulatory pressures affecting many Medicare Advantage-focused carriers.